294 related articles for article (PubMed ID: 26906088)
21. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
Ishikawa A; Muro Y; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
[TBL] [Abstract][Full Text] [Related]
22. Analytic and Clinical Validity of Myositis-Specific Antibodies by Line-Blot Immunoassay Is Essential.
Tseng CW; Satoh M; Hasegawa T; Tanaka S; Chen YM
J Clin Rheumatol; 2024 Jan; 30(1):e23-e28. PubMed ID: 37983669
[TBL] [Abstract][Full Text] [Related]
23. Myositis-specific autoantibodies in clinical practice: Improving the performance of the immunodot.
Bories E; Fortenfant F; Pugnet G; Renaudineau Y; Bost C
Semin Arthritis Rheum; 2022 Aug; 55():151998. PubMed ID: 35427882
[TBL] [Abstract][Full Text] [Related]
24. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
[TBL] [Abstract][Full Text] [Related]
25. Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
J Dermatol; 2022 Apr; 49(4):441-447. PubMed ID: 34967032
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
[TBL] [Abstract][Full Text] [Related]
27. Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study.
Leurs A; Dubucquoi S; Machuron F; Balden M; Renaud F; Rogeau S; Lopez B; Lambert M; Morell-Dubois S; Maillard H; Béhal H; Hachulla E; Launay D; Sobanski V
Joint Bone Spine; 2021 Jan; 88(1):105048. PubMed ID: 32653653
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study.
Montagnese F; Babačić H; Eichhorn P; Schoser B
J Neurol; 2019 Jun; 266(6):1358-1366. PubMed ID: 30840145
[TBL] [Abstract][Full Text] [Related]
29. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias.
De Sadeleer LJ; De Langhe E; Bodart N; Vigneron A; Bossuyt X; Wuyts WA
Lung; 2018 Jun; 196(3):329-333. PubMed ID: 29532165
[TBL] [Abstract][Full Text] [Related]
31. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.
Koenig M; Fritzler MJ; Targoff IN; Troyanov Y; Senécal JL
Arthritis Res Ther; 2007; 9(4):R78. PubMed ID: 17688695
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of autoantibody screening in patients with autoimmune myositis.
Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
[TBL] [Abstract][Full Text] [Related]
34. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
35. Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study.
Infantino M; Palterer B; Biagiotti R; Almerigogna F; Benucci M; Damiani A; Grossi V; Azzurri A; Casprini P; Bacci G; Giudizi MG; Manfredi M
Immunol Res; 2018 Feb; 66(1):74-78. PubMed ID: 29159696
[TBL] [Abstract][Full Text] [Related]
36. [Reliability and clinical utility of Enzyme-linked immunosorbent assay for detection of anti-aminoacyl-tRNA synthetase antibody].
Abe T; Tsunoda S; Nishioka A; Azuma K; Tsuboi K; Ogita C; Yokoyama Y; Furukawa T; Maruoka M; Tamura M; Yoshikawa T; Saito A; Sekiguchi M; Azuma N; Kitano M; Matsui K; Hosono Y; Nakashima R; Ohmura K; Mimori T; Sano H
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(2):140-4. PubMed ID: 27212600
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of anti-HMGCR and anti-MDA5 identified by an unlabeled immunoprecipitation assay in a chinese patient cohort with myositis.
Huang L; Wang L; Yang Y; Chen H; Liu Y; Liu K; Liu M; Xiao Y; Zuo X; Li Y; Luo H; Zhang H; Xiao X
Medicine (Baltimore); 2018 Nov; 97(47):e13236. PubMed ID: 30461626
[TBL] [Abstract][Full Text] [Related]
38. Distinct dermatomyositis populations are detected with different autoantibody assay platforms.
Fiorentino DF; Gutierrez-Alamillo L; Hines D; Yang Q; Casciola-Rosen L
Clin Exp Rheumatol; 2019; 37(6):1048-1051. PubMed ID: 31376258
[TBL] [Abstract][Full Text] [Related]
39. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
[TBL] [Abstract][Full Text] [Related]
40. A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting.
Kuwana M; Okazaki Y
Mod Rheumatol; 2023 Apr; 33(3):543-548. PubMed ID: 35662349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
